

# Neuromod Devices Summarised Press Kit

- Neuromod Devices Ltd is a medical technology company specialising in the design and development of neuromodulation technologies to address the clinical needs of underserved patient populations who live with chronic and debilitating conditions.
- Neuromod was founded in 2010 by Dr. Ross O'Neill based on technology developed at Maynooth University, Dublin.
- We have more than 60 employees spanning our offices in Dublin, Forchheim, Bavaria and Oak Brook, Illinois.
- We have raised more than €26 million in venture finance supported by leading investment partners who share and believe in our mission to improve the quality of life of underserved patient populations.
- Neuromod developed Lenire, the first non-invasive bimodal neuromodulation tinnitus treatment device shown to soothe and relieve tinnitus in a large-scale clinical trial.
- Lenire has CE-mark certification for the treatment of tinnitus under the supervision of an appropriately qualified healthcare professional in Europe and is currently available in 8 European countries.
- In 2016, Neuromod commenced its TENT-A1 large-scale clinical trial of Lenire, a randomised double-blind multi-arm trial in 326 patients with 12 months long-term post-treatment follow-up.
- In 2018, Neuromod commenced its TENT-A2, a randomised double-blind multi-arm trial in 191 patients with 12 months long-term post-treatment follow up
- In October 2020, we published the results of our large-scale clinical trial, TENT-A1, as the cover story in Science Translational Medicine, demonstrating the safety and efficacy of Lenire in reducing tinnitus symptom severity.

If you're interested in more information about Neuromod or would like a more detailed press kit, please contact [neil.doyle@neuromoddevices.com](mailto:neil.doyle@neuromoddevices.com)